Platelet activating factor mediates cardiopulmonary dysfunction during graded bacteremic shock

Journal of Trauma - Injury, Infection and Critical Care

Volumn 41, Issue 2, 1996, Pages 291-297

  Woolley, Daniel S ^a   Puglisi, Roberto N ^a   Quinn, James V ^a   Slotman, Gus J ^a,b  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b Department of Surgery ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; APAFANT; ICOSANOID; LEUKOTRIENE B4; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE E4; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; THROMBOXANE B2; TUMOR NECROSIS FACTOR ALPHA;

AEROMONAS HYDROPHILA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL GAS; BACTEREMIA; CARDIOPULMONARY HEMODYNAMICS; CENTRAL VENOUS PRESSURE; CONFERENCE PAPER; CONTROLLED STUDY; HEART RATE; HEART STROKE VOLUME; INTRAVENOUS DRUG ADMINISTRATION; LUNG CAPILLARY PRESSURE; LUNG VASCULAR RESISTANCE; MEAN ARTERIAL PRESSURE; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; SEPTIC SHOCK; SWINE; SYSTEMIC VASCULAR RESISTANCE;

EID: 0029741358     PISSN: 00225282     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005373-199608000-00016     Document Type: Conference Paper

References (26)

1. Anderson BO, Bensard DD, Harken AH: The role of platelet activating factor and its antagonists in septic shock, sepsis and multiple organ failure. Surgery 172:415, 1991
2. Bussolino F, Porcellini MG, Varese L, et al: Intravascular release of platelet activating factor in children with sepsis. Thromb Res 48:61, 1987
3. Inarrea P, Gomez-Cambronero J, Pascual J, et al: Synthesis of PAF-acether and blood volume changes in gram negative sepsis. Immunopharmacology 9:45, 1985
4. Ruggiero V, Chiapparino C, Mangaello S, et al: Beneficial effects of a novel platelet-activating factor receptor antagonist, ST 899, on endotoxin-induced shock in mice. Shock 2:275, 1994
5. Keser C, Siebeck M, Weipert J, et al: Pretreatment of PAF antagonist WEB 2086 attenuates pulmonary dysfunction in porcine endotoxin shock. Circulatory Shock 34:136, 1991
6. McCormick DG, Barnes PJ, Evans TW: Platelet-activating factor: Evidence against a role in the hypoxic pulmonary vasoconstriction. Crit Care Med 18:1398, 1990
7. Sun X, Hsueh W: Platelet-activating factor produces shock, in vivo complement activation, and tissue injury in mice. J Immunol 147:509, 1991
8. Rabinovici R, Yue TL, Farhat M, et al: Platelet activating factor (PAF) and tumor necrosis factor-α (TNF) interactions in endotoxemic shock: Studies with BN 50739, a novel PAF antagonist. J Pharmacol Exp Ther 255:256, 1990
9. Fletcher JR, Moore JM, Hubbard M, et al: Platelet activating factor (PAF) reverses tumor necrosis factor (TNF)-induced mortality. Circ Shock 34:135, 1991
10. Dubois EF: Basal Metabolism in Health and Disease. Philadelphia, Lea & Febiger, 1936
11. Slotman GJ, Quinn JV, Burchard KW, et al: Thromboxane interaction with cardiopulmonary dysfunction in graded bacterial sepsis. J Trauma 24:803, 1984
12. Slotman GJ, Quinn JV, Burchard KW, et al: Thromboxane, prostacyclin and the hemodynamic effects of graded bacteremic shock. Circ Shock 16:395, 1985
13. Slotman GJ, Teplitz C, et al: Interaction of thromboxane A2 and tissue pathology during graded bacteremia. J Trauma 27:167, 1987
14. 2 mediates hemodynamic and respiratory dysfunction in graded bacteremia. Surgery 100:214, 1986
15. Casals-Stenzel J, Muacevic G, Weber KH: WEB-2086, a new and specific antagonist of platelet activating factor (PAF) in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol 334:R44, 1986
16. Evans TW, Dent G, Rogers DF, et al: Effect of a PAF antagonist, WEB 2086, on airway microvascular leakage in the guinea-pig and platelet aggregation in man. Br J Pharmacol 94:164, 1988
17. Casals-Stenzel J: Effects of WEB 2086, a novel antagonist of platelet activating factor, in active and passive anaphylaxis. Immunopharmacology 13:117, 1987
18. Winer BJ: Statistical Principles in Experimental Design. 2nd ed. New York, McGraw Hill, 1971, pp 191-218
19. Siebeck M, Kohl J, Endres S, et al: Delayed treatment with platelet activating factor receptor antagonist WEB 2086 attenuates pulmonary dysfunction in porcine endotoxin shock. J Trauma 37:745, 1994
20. Giembycz M, Kroegel C, Barnes P: Platelet activating factor stimulates cyclo-oxygenase activity in guinea pig eosinophils. J Immunol 144:3489, 1990
21. Byrne K, Sessler C, Carey D, et al: Platelet-activating factor in porcine pseudomonas acute lung injury. J Surgical Res 50:111, 1991
22. Filep J, Braquet P, Mozes T: Interactions between platelet-activating factor and prostanoids during mesenteric ischemia-reperfusion-induced shock in the anesthetized dog. Circ Shock 35:1, 1991
23. Slotman GJ, Burchard KW, Williams JJ, et al: Interaction of prostaglandins, activated complement, and granulocytes in clinical sepsis and hypotension. Surgery 99:744, 1986
24. Baum T, Heard S, Feldman H, et al: Endotoxin-induced myocardial depressioning rats: Effect of ibuprofen and SDZ 64-688, a platelet activating factor receptor antagonist. J Surg Res 48:629, 1990
25. 2 mediates platelet-activating factor-induced increase in total vascular resistance in the isolated rat hindquarter (Abstract). Shock 1(suppl):1-71, 1994
26. Maier RV, Hahnel GB, Flectcher JR: Platelet-activating factor augments tumor necrosis factor and procoagulant activity. J Surg Res 52:258, 1992